Peyrin-Biroulet L - Search Results

1

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.

Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L; International Consortium for Therapeutic Drug Monitoring. Papamichael K, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):171-185. doi: 10.1016/S2468-1253(21)00223-5. Lancet Gastroenterol Hepatol. 2022. PMID: 35026171 Free PMC article. Review.

2

Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.

Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Peyrin-Biroulet L, et al. World J Gastroenterol. 2007 Apr 28;13(16):2328-32. doi: 10.3748/wjg.v13.i16.2328. World J Gastroenterol. 2007. PMID: 17511032 Free PMC article. Clinical Trial.

3

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. doi: 10.1016/j.cgh.2008.03.014. Clin Gastroenterol Hepatol. 2008. PMID: 18550004

4

Early combined immunosuppression in Crohn's disease.

Danese S, Peyrin-Biroulet L. Danese S, et al. Lancet. 2008 Jun 14;371(9629):1996; author reply 1996-7. doi: 10.1016/S0140-6736(08)60862-4. Lancet. 2008. PMID: 18555908 No abstract available.

5

Crohn's disease: beyond antagonists of tumour necrosis factor.

Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Lancet. 2008 Jul 5;372(9632):67-81. doi: 10.1016/S0140-6736(08)60995-2. Lancet. 2008. PMID: 18603161 Review.

6

Step-up and top-down approaches to the treatment of Crohn's disease: early may already be too late.

Peyrin-Biroulet L, Bigard MA, Malesci A, Danese S. Peyrin-Biroulet L, et al. Gastroenterology. 2008 Oct;135(4):1420-2. doi: 10.1053/j.gastro.2008.08.017. Epub 2008 Sep 4. Gastroenterology. 2008. PMID: 18773901 No abstract available.

7

A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.

Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. Roblin X, et al. Am J Gastroenterol. 2008 Dec;103(12):3115-22. doi: 10.1111/j.1572-0241.2008.01743.x. Am J Gastroenterol. 2008. PMID: 19086961 Retracted. Clinical Trial.

8

Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease.

Peyrin-Biroulet L, Colombel JF, Sandborn WJ. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1139. doi: 10.1016/j.cgh.2009.05.012. Epub 2009 May 22. Clin Gastroenterol Hepatol. 2009. PMID: 19465159 No abstract available.

9

"Comment on a retraction": author response.

Roblin X, Peyrin-Biroulet L, Phélip JM, Nancey S, Flourié B. Roblin X, et al. Am J Gastroenterol. 2009 Jul;104(7):1864-5. doi: 10.1038/ajg.2009.351. Am J Gastroenterol. 2009. PMID: 19574985 No abstract available.

10

Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health.

Peyrin-Biroulet L, Cieza A, Sandborn WJ, Kostanjsek N, Kamm MA, Hibi T, Lémann M, Stucki G, Colombel JF. Peyrin-Biroulet L, et al. Inflamm Bowel Dis. 2010 Jan;16(1):15-22. doi: 10.1002/ibd.21010. Inflamm Bowel Dis. 2010. PMID: 19610077

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,037 results

Search Page